TCR2 Therapeutics has been granted a patent for T-cell receptor fusion proteins (TFPs) that target tumor cell antigens. The patent covers engineered T cells expressing TFPs for disease treatment, including cancer. The recombinant nucleic acid includes specific sequences encoding the TFP structure and antigen binding domains. GlobalData’s report on TCR2 Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on TCR2 Therapeutics, CAR-T cell based therapies was a key innovation area identified from patents. TCR2 Therapeutics's grant share as of January 2024 was 15%. Grant share is based on the ratio of number of grants to total number of patents.
Recombinant nucleic acid encoding tcr fusion protein for cancer treatment
A recently granted patent (Publication Number: US11851491B2) discloses a recombinant nucleic acid that encodes a T-cell receptor (TCR) fusion protein (TFP). The TFP comprises a TCR subunit with specific domains and antigen binding domains that bind to different antigens. The TFP forms a multimeric TCR complex when expressed on the surface of a T cell, along with endogenous TCR and CD3 chains. The patent also covers variations in the antigen binding domains, TCR chains, and the formation of different multimeric TCR complexes.
Furthermore, the patent includes claims for pharmaceutical compositions comprising human T cells expressing the recombinant nucleic acid, along with a pharmaceutically acceptable excipient. Another aspect of the patent involves a recombinant nucleic acid encoding two different TFPs linked by a cleavage site, each binding to distinct antigens and forming separate multimeric TCR complexes on T cells. The patent also covers variations in the TCR chains, antigen binding domains, and the inclusion of a VH domain. These innovative technologies hold promise for enhancing T cell therapies for various diseases by targeting multiple antigens simultaneously.
To know more about GlobalData’s detailed insights on TCR2 Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
